Beyond Oncology — China's Breakthroughs in Rare Disease, Neurodegeneration, and Next-Generation Therapeutics

I. Introduction: The Frontiers Beyond Cancer

China's achievements in oncology — the world's first bispecific ADC, the first CAR-T for solid tumors, a comprehensive EGFR-TKI arsenal — are well documented. Less visible, but arguably equally consequential, are breakthroughs in therapeutic areas that have historically been neglected: rare genetic diseases, neurodegenerative conditions, and next-generation drug modalities.

This article examines four frontier areas where Chinese innovation is making a measurable difference: BCD gene therapy, Alzheimer's disease treatment access, siRNA therapeutics for ALS, and the broader pipeline of rare disease therapies.

II. BCD Gene Therapy: The World's First Treatment for a Rare Blinding Disease

Bietti's crystalline dystrophy (BCD) is an inherited retinal degeneration caused by mutations in the CYP4V2 gene. It is a rare disease globally — but it is disproportionately prevalent in East Asian populations, with an estimated 60,000 to 140,000 patients in China alone. There is currently no approved treatment anywhere in the world. Most patients experience irreversible vision loss beginning in middle age.

In August 2026, Beijing Chigenovo's ZVS101e injection (哌普锐基注射液) was formally accepted by the CDE and granted priority review status. This is the world's first gene therapy for BCD to reach the regulatory review stage.

Key details:

Aspect	Detail
Drug	ZVS101e injection
Developer	Beijing Chigenovo Co.
Target	CYP4V2 biallelic mutation-positive BCD
Status	NDA accepted, priority review granted (August 2026)
Priority review timeline	130 working days (vs. standard 200)
Expected approval window	Q1 2027
Global context	One of only three ophthalmic gene therapies worldwide to reach clinical-stage development

The strategic significance of this program extends beyond BCD itself. It demonstrates that Chinese companies are capable of identifying and developing therapies for diseases that are rare globally but have concentrated patient populations in China. This "orphan disease, non-orphan population" dynamic creates a commercial rationale for development that may be absent in Western markets.

For international patients — particularly those of East Asian descent — China is the only jurisdiction where a BCD gene therapy is approaching regulatory approval.

III. Alzheimer's Disease: From Diagnostic to Therapeutic Access

Alzheimer's disease (AD) represents one of the most significant unmet needs in global healthcare. China has approximately 10 million AD patients — the largest population in the world. In 2026, two disease-modifying anti-amyloid antibodies became accessible in China:

Drug	Developer	NMPA Approval	Key Feature
Lecanemab (乐意保®)	Eisai/Biogen	January 2024 (IV); September 2026 (SC auto-injector)	First anti-amyloid antibody approved in China; subcutaneous formulation enables home administration
Donanemab (记能达®)	Eli Lilly	December 2024	Alternative anti-amyloid antibody with different dosing schedule

The September 2026 approval of subcutaneous lecanemab (a weekly auto-injector that delivers the drug in approximately 30 seconds) represents a significant practical advance. It eliminates the need for intravenous infusions, which require clinic visits and healthcare professional administration.

Critically for international patients, both lecanemab and donanemab were included in China's first commercial health insurance innovative drug directory effective January 2026. This creates a structured payment pathway that, while not directly accessible to non-Chinese insurance holders, provides transparency on pricing and establishes China as a jurisdiction where these therapies are actively reimbursed rather than merely available at full self-pay cost.

The broader significance is that China has moved from being a lagging market for AD therapies to one where disease-modifying treatments are approved, reimbursed, and increasingly accessible through multiple administration routes — including the world's first subcutaneous auto-injector for an anti-amyloid antibody.

IV. siRNA Therapeutics: RAG-17 for SOD1-ALS

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with a median survival of 3–5 years. Approximately 10–20% of familial ALS cases and 1% of sporadic cases are caused by SOD1 mutations.

On July 15, 2026, a collaborative team from Beijing Tiantan Hospital (Professor Wang Yilong) and Ractigen Therapeutics (Professor Li Longcheng) published first-in-human clinical data for RAG-17, a siRNA therapeutic targeting SOD1-ALS, in Nature Medicine.

Clinical results from the first-in-human trial:

Endpoint	Result
Patients treated	6
Route of administration	Intrathecal injection
CSF SOD1 protein reduction	56–69%
Plasma neurofilament light chain reduction	52–62%
Serious adverse events	None reported
Adverse events	Mild-to-moderate (muscle tremor, transient ALT elevation); all resolved

The biomarker reductions — particularly the 52–62% reduction in plasma neurofilament light chain, a marker of axonal degeneration — represent objective evidence of disease modification. As of August 2026, the Phase II trial (NCT06556394) had completed enrollment and first dosing of all subjects across five leading Chinese centers.

RAG-17 is the first siRNA therapy for SOD1-ALS developed and clinically validated entirely by a Chinese team, and it has received FDA Orphan Drug Designation.

V. The Broader Rare Disease Pipeline

Beyond BCD and ALS, China's rare disease therapeutic pipeline has expanded significantly:

• Homozygous familial hypercholesterolemia (HoFH): AAV gene therapy (NGGT006) achieved sustained LDL-C reduction from 11 mmol/L to below 1.8 mmol/L in a Phase I trial published in Nature Medicine (June 2026).
• Spinal muscular atrophy (SMA): Multiple gene therapy programs are in clinical development at Shanghai Children's Medical Center and other centers.
• Hemophilia A and B: AAV-based gene therapies are advancing through clinical trials at Peking Union Medical College Hospital and other institutions.

The common thread across these programs is that they address diseases where (a) the genetic basis is well understood, (b) conventional therapies are inadequate or unavailable, and (c) the patient population — while rare — is sufficiently large in China to support clinical development.

VI. What This Means for International Patients

Therapeutic Area	China's Unique Advantage	Access Status
BCD gene therapy	World's first; concentrated patient population	NDA under priority review; expected Q1 2027
Alzheimer's disease	Both anti-amyloid antibodies approved; SC formulation available	Commercially available; reimbursed through commercial insurance directory
SOD1-ALS siRNA	First Chinese siRNA for ALS; compelling biomarker data	Phase II enrollment complete; Phase III expected
HoFH gene therapy	First HoFH gene therapy trial in China; single-dose potential	Phase I completed; expansion planned

VII. Conclusion

China's innovation in frontier therapeutic areas reflects a strategic logic that extends beyond commercial considerations. For diseases like BCD — rare globally but concentrated in East Asia — China offers the only realistic pathway to a therapy. For diseases like Alzheimer's, China's large patient population and regulatory efficiency have made it an early adopter of disease-modifying therapies. And for next-generation modalities like siRNA and AAV gene therapy, Chinese researchers are generating first-in-human data that establishes the country as a genuine innovator rather than a follower.

For international patients with rare diseases or neurodegenerative conditions, China's frontier therapeutic programs represent a concrete and increasingly realistic treatment option — not merely a future promise.